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Dear Editor 
One of the primary risk factors in the development of cancer is 
older age. The demographic shift to an ageing population has 
given rise to an increased number of older patients with cancer. 
The extreme heterogeneity within this population renders 
applying standardised treatment pathways hazardous1. 
Disparities in physiological reserve and an increased risk of 
multiple comorbidities further exacerbates the complexity of 
cancer treatment management in older patients2. Individual 
modifications to tailor treatment for each specific patient would 
be the gold standard; thus, detailed patient assessment 
providing a comprehensive health profile in addition to existing 
diagnostic test results are paramount when devising a 
personalised treatment care approach3.  
Recognition of this has led to interest in the potential value of 
the Comprehensive Geriatric Assessment (CGA), to guide 
appropriate treatment selection in this patient cohort. CGA is a 
multidimensional tool to assess individual domains.  These 
domains typically include: functional status (FS), 
comorbidities, nutrition, performance status (PS), 
psychological, cognition, social support, and medication, and 
collectively determine the functional status of the patient4. 
Although CGA has been validated in a geriatric setting, it has 
not yet been validated in an oncological setting. A number of 
assessment tools have been designed to assess each of the 
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domains but there is no agreed format for CGA in oncology5. In 
addition to the lack of standardised format, CGA has also been 
criticised for being too time-consuming to complete and 
therefore difficult to incorporate routinely into a busy oncology 
setting6. Other screening tools have been developed to address 
this problem, such as the Vulnerable Elders Survey-13 (VES-
13). The VES-13 is a patient self-rated, questionnaire with a 
total of 13 items to identify vulnerable older patients that 
require further assessment with CGA7. 
Although significant feasibility work by leading experts in this 
field has already been completed 8, 9, much of this research was 
in the US; we propose further feasibility work in UK hospitals 
is necessary, since implementation is likely to differ 
considerably. The aim of this study therefore, was to address 
the feasibility of using CGA and VES-13 in outpatient older 
adults with cancer, in England.  Providing data to inform the 
design of a definitive randomised controlled trial (RCT), where 
these tools will be tested as an intervention to guide cancer 
treatment with regard to patient relevant outcomes. 
Methods 
Study population 
This single centre, feasibility study was conducted in the 
oncology outpatient department of the Queen’s centre, Castle 
Hill Hospital, Hull, from October 2014 until July 2015 in 
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patients aged 70 and older with a newly diagnosed cancer. A 
conservative eligible: consent ratio of 4:1 was considered 
feasible in terms of a subsequent trial given the age of the 
population. This study, including method of consent, was 
approved by Research Ethics Committee (REC) and Hull and 
East Yorkshire (HEY) trust R&D and was conducted in 
accordance with Good Clinical Practice guidelines and the 
Declaration of Helsinki. Written informed consent was 
obtained from all participants. 
Data collection 
All consenting patients completed both assessment tools in full, 
consecutively in clinic with the help (if required) from a 
research nurse, starting with CGA and then the VES-13. 
Briefly, our CGA comprised of: Lawton’s Instrumental 
Activities of Daily Living (IADL) to assess FS, diagnosed 
comorbidities according to Charlson comorbidity index, an 
internal screening questionnaire used routinely in the cancer 
centre was used to assess nutrition (see online supplemental 
appendix 1), Eastern Cooperative Oncology Group (ECOG) 
was used to assess performance status (PS), Geriatric 
Depression Scale (GDS) to assess psychological status, 
cognitive impairment was assessed in a two step process (as 
advised by our geriatrician team member (DH)), all 100 
patients completed the Abbreviated Mental Test Score 
(AMTS), since a score of  ≤8 is indicative of likely impairment, 
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patients with this score were also assessed using Folstein’s 
Mini-Mental State Examination (MMSE), finally, participant 
medication information was obtained through medical notes 
and patient self-report. In accordance with previously published 
values, a cut-off score of impairment in  two or more CGA 
domains signified vulnerability of an increased risk of poor 
treatment outcome8. Further detail on individual assessment 
scores can be obtained from the authors. The VES-13 screening 
tool has a maximum score of ten, the total overall score range 
in our study was zero (lowest risk) and ten (highest risk).  In 
order to categorise participants in to vulnerable and not 
vulnerable, a cut-off score of three was used, whereby 
participants scoring three or more with the VES-13 tool were 
classified vulnerable7. 
Statistical analysis 
Descriptive analyses are presented to describe patients and 
clinical baseline characteristics, assessment outcomes and 
patient clinical outcomes after six month follow-up. Post hoc 
analyses to test inter-rater reliability between CGA and VES-13 
was tested with Cohen’s kappa. STATA software (version 
14.0) was used for all statistical analyses. 
Results 
A total of 100 patients were recruited (mean age 78 years, SD 
6, range 70-97 years; 50 (50%) were women.  There were 
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sixteen different cancer types, colorectal cancer was the most 
frequent (26%).  Almost 50% of patients had late stage cancer 
at diagnosis.  Over half (66%) of the study population’s 
intended treatment plan included chemotherapy. According to 
IADL, 60% of participants achieved a perfect score of eight, 
indicative of fully independent living, however, ECOG PS 
differed in that 47% of patients were rated as ECOG Zero 
indicating they were fully active. A quarter of patients (25%) 
scored high risk for depression with the GDS (further 
assessment outcomes detailed in table one).  Primary outcomes 
for this study were recruitment and assessment times 
(secondary outcome results detailed in online supplemental).  
Average monthly recruitment rate was 11.1 and screen to 
consent ratio was 2.39:1 (details of study phase progression in 
figure one).  The mean assessment completion time for the 
CGA was 16.3 minutes (SD 9.2, range 5-80 minutes). The 
mean assessment completion time for the VES-13 was 5.2 
minutes (SD 3.6, range 1-35). Over half, 54 (54%), of 
participants were classed as vulnerable according to CGA, 
whilst almost half, 46 (46%) were classed as vulnerable 
according to VES-13 (score of 3 or more). Moderate agreement 
was observed between the CGA and VES-13 (Cohen’s kappa 
value 0.52, 95% CI 0.35 to 0.69, p = <0.001). 
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Discussion 
This feasibility study shows that recruitment to a trial using 
CGA and VES is feasible with only fifteen percent of 
approached patients declining consent. Time to complete the 
tools is reasonable in the context of routine clinical practice. 
The assessment tools selected for this study were brief in nature 
and could be self-completed during clinical waiting times, 
factors which may have contributed to our high participation 
rates. Other study data were collected from clinical records; 
thus minimising participant burden. Time constraints in busy 
routine cancer practice is a major concern regarding use of 
CGA in older adults.  As there is no agreed CGA format, 
completion time depends on the format chosen. Mean 
completion time for the CGA in this study was consistent with 
previous studies using a similar format 8, 9. 
Currently, performance status as measured by the ECOG or 
Karnofsky Performance Status (PS) tools are widely used in 
oncology and used as a guide to treatment decisions.  In our 
study, 83% of our participants had an ECOG PS of less than 
one; however, only half of the studies patients were classed as 
non-vulnerable by the CGA or VES-13. This supports findings 
from another study, suggesting CGA can help identify issues 
not necessarily identifiable by PS alone10. This prospective, 
consecutive study provides real-life out-patient data and 
included older patients with a variety of different solid cancer 
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types in order to test broad feasibility of CGA use. However, 
the study was not designed to detect any particular effect size, 
and the observations therefore support investigation in an 
appropriately powered study.  
Strengths and limitations 
The study population was derived from a single centre. 
Recruitment from outpatient clinic may have caused 
unintentional selection bias to yield a healthier population of 
older patients with cancer; consistent with a high percentage 
(66%) of participants with a treatment plan including 
chemotherapy.  In future studies, effort should be made to 
recruit a cross section of participants with a range of health 
profiles.  
Implications for future practice and research 
Study design of a future RCT was not tested (no randomisation) 
and thus willingness to be randomised needs further assessment 
prior to progression to a definitive trial.  The assessments were 
carried out by a study research nurse (RN). In order for the 
CGA or VES-13 to be tested in an RCT in a manner which 
could provide a new standard of care, the assessments need to 
be carried out by a clinical nurse as part of routine care. 
Therefore, further work is needed to identify the time needed 
for clinical nurses to be trained and to deliver the assessment, 
and the acceptability of doing so. A comparison between RN and 
physician assessment was not made; this would be interesting to 
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examine in future work. The CGA results can be made available 
to the consultant rapidly, for both discussion with the patient 
and to assist with treatment decisions. Further work to 
determine whether and how the results of the CGA can 
influence treatment decisions is ongoing. The shorter 
questionnaire, the VES-13, may be useful as a screening tool. 
Conclusion 
This feasibility study is the first in a series of preparatory 
research studies aimed at informing the design and construct of 
a definitive RCT to test whether routine CGA assessment 
improves clinical outcomes in the older adult with cancer. We 
have shown recruitment is feasible in terms of willingness to be 
assessed and complete study questionnaires. CGA completion 
times in an outpatient clinic setting are reasonable.  
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